China's Walvax Biotechnology has recruited most of the 28,000 participants needed for a large clinical trial of its mRNA COVID-19 vaccine candidate, a senior company official said on Thursday.

China has yet to approve a Chinese vaccine of the novel messenger RNA (mRNA) technology and has yet to import a foreign mRNA vaccine.